Egalet Reports Fourth Quarter and Full Year 2015 Financial Results

Mar 08, 2016, 06:00 ET from Egalet Corporation

WAYNE, Pa., March 8, 2016 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today reported financial results for the fourth quarter and year ended December 31, 2015.  

"In the fourth quarter Egalet submitted an NDA for ARYMO ER, an abuse-deterrent, extended-release morphine product candidate developed using our proprietary Guardian™ Technology," said Bob Radie, Egalet's president and chief executive officer. "The recent acceptance of the ARYMO ER file by the FDA takes us one step closer to adding to our portfolio of treatment options for patients suffering from pain."

Fourth Quarter and Full Year Financial Results:

  • Cash Position: As of December 31, 2015, Egalet had cash and marketable securities totaling $145.7 million.
  • Revenue: There were net product sales of $4.2 million for the year ended December 31, 2015 compared to $0 for the year ended December 31, 2014. For the fourth quarter ended December 31, 2015, there were net product sales of $2.1 million compared to $0 for the fourth quarter of 2014. The increase was due to the launch of SPRIX® (ketorolac tromethamine) Nasal Spray and OXAYDO™ (oxycodone HCI, USP) tablets for oral use only –CII. Related party revenues increased from $1.9 million for the year ended December 31, 2014 to $18.6 million for the year ended December 31, 2015. The increase was due to the termination of the collaboration agreement with Shionogi which resulted in the recognition of $16.9 million in related party revenues that otherwise would have been classified as deferred revenue as of December 31, 2015 and recognized as revenue over the life of the agreement.
  • Cost of Sales: Cost of sales was $3.3 million for the year ended December 31, 2015 and $2.6 million for the fourth quarter of 2015 related to the sales of SPRIX and OXAYDO, which began in 2015. Of the cost of sales in 2015, $1.7 million is related to an inventory write down predominantly due to SPRIX product expiration which was purchased from Luitpold as part of the initial acquisition of the product. The cost of sales for SPRIX (excluding product amortization rights) reflects the fair value of finished goods inventory that was acquired as part of the acquisition and was dispensed to patients during the period. The cost of sales for OXAYDO (excluding product amortization rights) reflects the average costs of inventory dispensed to patients during the period.
  • G&A Expenses: General and administrative expenses increased to $26.5 million for the year ended December 31, 2015 compared to $15.7 million for 2014. General and administrative expenses for the fourth quarter ended December 31, 2015 were $10.3 million compared to $4.0 million for fourth quarter ended December 31, 2014. This was primarily attributable to FDA regulatory fees and increases in salary and benefits due to an increase in headcount, as well as an increase in professional and administrative fees as Egalet expanded operations in 2015. These increases were offset by a decrease in stock compensation expense.
  • S&M Expenses: Sales and marketing expenses increased to $16.3 million for the year ended December 31, 2015 from $946,000 in the year ended December 31, 2014 and sales and marketing expenses increased to $5.2 million for the fourth quarter ended December 31, 2015 compared to $420,000 for the fourth quarter ended December 31, 2014. The increase in sales and marketing expenses was related to the establishment of the commercial operations in the United States and launch activities for SPRIX and OXAYDO. Expenses for the year ended December 31, 2015 consisted primarily of salary, benefits and costs related to the contract sales force, as well as sales and marketing operations for SPRIX and OXAYDO.
  • R&D Expenses: Research and development expenses increased to $27.1 million for the year ended December 31, 2015 from $22.4 million for the year ended December 31, 2014. Research and development expenses for the fourth quarter ended December 31, 2015 were $7.3 million compared to research and development expenses of $5.9 million for the same period in 2014. The increase was driven primarily by an increase in development costs for Egalet-002 offset by a decrease in ARYMO ER development expenses and a decrease in stock compensation expense.
  • Interest Expense: Interest expense increased to $7.5 million for the year ended December 31, 2015 from $7.1 million for the same period in 2014. Interest expense for the fourth quarter ended December 31, 2015 was $2.3 million compared to interest income of $4,000 for the same period in 2014. Interest expense for the year ended December 31, 2014 was primarily attributable to the recognition of the unamortized premium upon conversion of related party senior convertible debt in connection with Egalet's initial public offering in February 2014. Interest expense for the year ended December 31, 2015 was primarily attributable to the interest expense on the 5.50% convertible notes and the Hercules loan.
  • Net Loss: Net loss for the year ended December 31, 2015 was $57.9 million, or $2.94 per share, compared to a net loss of $43.2 million, or $2.97 per share, for the year ended December 31, 2014. The net loss for the fourth quarter ended December 31, 2015 was $6.8 million, or $0.28 per share, compared to a net loss of $8.5 million, or $0.52 per share, for the quarter ended December 31, 2014. 

About Egalet Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has two approved products: OXAYDO™ (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. In addition, using its proprietary Guardian™ Technology, Egalet is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, ARYMO ER ER®, formerly known as Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Full additional information on Egalet, please visit egalet.com. For full prescribing information on SPRIX, please visit sprix.com and for OXAYDO please visit oxaydo.com. For full prescribing information on SPRIX, including the black box warning, please visit sprix.com. For full prescribing information on OXAYDO, please visit oxaydo.com.

Safe Harbor Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of Egalet's clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet's ability to obtain regulatory approval of Egalet's product candidates; Egalet's ability to maintain the intellectual property position of Egalet's products and product candidates; Egalet's ability to identify and reliance upon qualified third parties to manufacture its products; Egalet's ability to service its debt obligations; Egalet's ability to find and hire qualified sales professionals; the receptivity in the marketplace and among physicians to Egalet's products; the success of products which compete with Egalet's that are or become available; general market conditions; and other risk factors described in Egalet's filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law. Investor and Media Contact: E. Blair Clark-Schoeb Senior Vice President, Communications Email: bcs@egalet.com Tel: 917-432-9275

Tables Follow

 

Egalet Corporation and Subsidiaries

Consolidated Balance Sheets (Unaudited)

(in thousands)

December 31, 

2014

2015

Assets

Current assets:

Cash and cash equivalents

$

52,738

$

46,665

Marketable securities, available for sale

-

99,042

Accounts receivable

-

295

Related party receivable

679

57

Inventory

-

1,837

Prepaid expenses and other current assets

698

1,295

Other receivables

1,011

1,047

Total current assets

55,126

150,238

Intangible assets, net

184

10,380

Property and equipment, net

4,417

7,801

Deposits and other assets

843

3,997

Total assets

$

60,570

$

172,416

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$

4,209

$

7,417

Accrued expenses

2,554

7,616

Deferred revenue

588

10,128

Debt - current

-

3,320

Other current liabilities

78

183

Total current liabilities

7,429

28,664

Debt - non-current portion, net

-

52,442

Deferred income tax liability

25

1,084

Deferred revenue - non-current portion

8,855

-

Derivative liability

-

656

Other liabilities

-

346

Total liabilities

16,309

83,192

Stockholders' equity

Common stock--$0.001 par value at December 31, 2014 and 2015; 75,000,000 shares authorized at December 31, 2014 and 2015; 17,283,663 and 25,085,554 shares issued and outstanding at December 31, 2014 and 2015, respectively

17

25

Additional paid-in capital

121,028

223,784

Accumulated other comprehensive loss

(171)

(41)

Accumulated deficit

(76,613)

(134,544)

Total stockholders' equity

44,261

89,224

Total liabilities and stockholders' equity

$

60,570

$

172,416

 

 

Egalet Corporation and Subsidiaries

Consolidated Statements of Operations (Unaudited)

(in thousands)

Year Ended

Three months ended

December 31, 

December 31, 

2014

2015

2014

2015

Revenues

Net product sales

$

$

4,184

$

$

2,119

Related party revenues

1,920

18,646

826

17,261

Total revenue

1,920

22,830

826

19,380

Cost and Expenses

Cost of sales (excluding amortization of product rights)

3,271

2,621

Amortization of product rights

1,958

490

General and administrative

15,715

26,474

4,037

10,294

Sales and marketing

946

16,289

420

5,154

Research and development

22,395

27,054

5,908

7,298

  Total costs and expenses

39,056

75,046

10,365

25,857

Loss from operations

(37,136)

(52,216)

(9,539)

(6,477)

Other (income) expense:

Change in fair value of derivative liability

(260)

(441)

Interest expense, net

7,079

7,477

(4)

2,340

Other gain

(1,045)

(864)

(1,028)

(862)

(Gain) loss on foreign currency exchange

(3)

82

(3)

(5)

6,031

6,435

(1,035)

1,032

Loss before provision (benefit) for income taxes

(43,167)

(58,651)

(8,504)

(7,509)

Provision (benefit) for income taxes

47

(718)

(37)

(722)

Net loss

$

(43,214)

$

(57,933)

$

(8,467)

$

(6,787)

Per share information:

Net loss per share of common stock, basic and diluted

$

(2.97)

$

(2.94)

$

(0.52)

$

(0.28)

Weighted-average shares outstanding, basic and diluted

14,556,927

19,738,042

16,402,952

24,353,109

 

Logo - http://photos.prnewswire.com/prnh/20140219/NY67493LOGO 

SOURCE Egalet Corporation



RELATED LINKS

http://www.egalet.com